- Home
- DSGN vs CCRN Comparison
DSGN vs CCRN Comparison
Compare DSGN & CCRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- CCRN
- Stock Information
- Founded
- DSGN 2017
- CCRN 1986
- Country
- DSGN United States
- CCRN United States
- Employees
- DSGN N/A
- CCRN N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- CCRN Professional Services
- Sector
- DSGN Health Care
- CCRN Consumer Discretionary
- Exchange
- DSGN Nasdaq
- CCRN Nasdaq
- Market Cap
- DSGN 418.1M
- CCRN 447.2M
- IPO Year
- DSGN 2021
- CCRN N/A
- Fundamental
- Price
- DSGN $8.78
- CCRN $10.92
- Analyst Decision
- DSGN Buy
- CCRN Hold
- Analyst Count
- DSGN 1
- CCRN 4
- Target Price
- DSGN $13.00
- CCRN $17.91
- AVG Volume (30 Days)
- DSGN 427.2K
- CCRN 407.7K
- Earning Date
- DSGN 11-05-2025
- CCRN 11-12-2025
- Dividend Yield
- DSGN N/A
- CCRN N/A
- EPS Growth
- DSGN N/A
- CCRN N/A
- EPS
- DSGN N/A
- CCRN N/A
- Revenue
- DSGN N/A
- CCRN $1,127,472,000.00
- Revenue This Year
- DSGN N/A
- CCRN N/A
- Revenue Next Year
- DSGN N/A
- CCRN N/A
- P/E Ratio
- DSGN N/A
- CCRN N/A
- Revenue Growth
- DSGN N/A
- CCRN N/A
- 52 Week Low
- DSGN $2.60
- CCRN $10.00
- 52 Week High
- DSGN $8.89
- CCRN $18.33
- Technical
- Relative Strength Index (RSI)
- DSGN 68.78
- CCRN 38.76
- Support Level
- DSGN $7.25
- CCRN $10.65
- Resistance Level
- DSGN $8.80
- CCRN $11.75
- Average True Range (ATR)
- DSGN 0.69
- CCRN 0.66
- MACD
- DSGN 0.12
- CCRN -0.10
- Stochastic Oscillator
- DSGN 93.42
- CCRN 20.21
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About CCRN Cross Country Healthcare Inc. $0.0001 Par Value
Cross Country Healthcare Inc is a provider of total talent management services, including strategic workforce solutions, contingent staffing, permanent placement and consultative services for healthcare customers. The company operates in two business segments: the nurse and allied staffing segment, which generates a vast majority of revenue, offers temporary and permanent placements of travel and local nurses and allied professionals, and other outsourcing services.: the Physician Staffing segment provides licensed practitioners across a broad array of specialties, as well as certified registered nurse anesthetists (CRNAs), nurse practitioners (NPs), and physician assistants (PAs) on temporary assignments. The company earns majority of its revenue from the United States.